Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 06, 2011

Bevacizumab Added to Erlotinib Provides No Benefit in NSCLC

The Lancet

 

Additional Info

The Lancet
Efficacy of Bevacizumab Plus Erlotinib Versus Erlotinib Alone in Advanced Non-Small-Cell Lung Cancer After Failure of Standard First-Line Chemotherapy (BeTa): a Double-Blind, Placebo-Controlled, Phase 3 Trial
Lancet 2011 May 28;377(9780)1846-1854, RS Herbst, R Ansari, F Bustin, P Flynn, L Hart, GA Otterson, G Vlahovic, C-H Soh, P O'Connor, J Hainsworth

Further Reading